The tuberculosis Drugs Market is growing rapidly with the Global Alliance for TB Drug Development gaining the U.S. FDA approval for its Pretomanid Tablets

 

Tuberculosis (TB) is the most prevalent pulmonary tuberculosis disease. Because of the very difficult and lengthy period of survival after becoming infected with pulmonary tuberculosis (PTC) and the associated often severe pulmonary and immune system disorders, the management of tuberculosis often revolves around early initiation of treatment. One of the primary factors fueling growth of the market in discussion is rapidly growing cases of tuberculosis worldwide. As per the World Health Organization (WHO), in 2019, around 1.4 million people died from tuberculosis worldwide with around 10 million people being diagnosed with the same. Such massive incidence of tuberculosis cases across the globe could potentially stimulate the tuberculosis drugs market.

As far as regional impact is considered, North America seems to be exhibiting significant traction in the tuberculosis drugs market. This can be attributed to the lower cost of TB drugs in the region. On the contrary, Asia Pacific is registering a positive outlook with rising prevalence of tuberculosis cases in India and other emerging economies. Recently, in August 2019, The Global Alliance for TB Drug Development (TB Alliance) received the U.S. Food and Drug Administration (FDA) approval for Pretomanid Tablets for the treatment of a specific type of highly treatment-resistant TB of lungs.

The core set of pulmonary tuberculosis drugs are saldol, bacrostat, rifampicin, or dioxin. These medications have different actions in different animals and humans. These drugs also differ in their metabolism in terms of frequency of release and elimination. That being said, there are certain challenges involved in the market that could limit future development. For instance, tuberculosis drugs have adverse effects on the patient such as itchy skin, upset stomach, nausea, rashes, diarrhea, and changes in eyesight. Besides, the high cost of XDR and MDR TB drugs could impede growth of the tuberculosis drugs market.

Recently, another interesting tuberculosis drug, i.e. muribethalin, has been discovered. This novel compound acts on tuberculosis-resistant strains of the infection by preventing their ability to digest protein. Studies in the field of MDR-TB and tuberculosis are still in their initial phase, although the developments so far indicate that the search for more powerful drugs is still going on. Since there is a high incidence of tuberculosis cases worldwide, government organizations in many countries have taken proactive initiatives to raise tuberculosis awareness among people. These initiatives include vaccination drives, additional funding for awareness campaigns, and the availability of high-quality drugs. For instance, in 2017, the Government of India announced the plan to eliminate TB by 2025. Such proactive initiatives could potentially augment growth of the tuberculosis drugs market.